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Abstract
Objectives To assess whether volumetric cerebrospinal fluid
(CSF) MRI can be used as a surrogate for brain atrophy as-
sessment and to evaluate how the T2 of the CSF relates to
brain atrophy.
Methods Twenty-eight subjects [mean age 64 (sd 2) years]
were included; T1-weighted and CSF MRI were performed.
The first echo data of the CSF MRI sequence was used to
obtain intracranial volume, CSF partial volume was measured
voxel-wise to obtain CSF volume (VCSF) and the T2 of CSF
(T2,CSF) was calculated. The correlation between VCSF / T2,CSF
and brain atrophy scores [global cortical atrophy (GCA) and
medial temporal lobe atrophy (MTA)] was evaluated.
Results Relative total, peripheral subarachnoidal, and ventric-
ular VCSF increased significantly with increased scores on the
GCA andMTA (R=0.83, 0.78 and 0.78 and R=0.72, 0.62 and
0.86). Total, peripheral subarachnoidal, and ventricular T2 of
the CSF increased significantly with higher scores on the
GCA and MTA (R=0.72, 0.70 and 0.49 and R=0.60, 0.57
and 0.41).
Conclusion A fast, fully automated CSF MRI volumetric se-
quence is an alternative for qualitative atrophy scales. The T2
of the CSF is related to brain atrophy and could thus be a
marker of neurodegenerative disease.
Key points
• A 1:11 min CSF MRI volumetric sequence can evaluate
brain atrophy.
• CSF MRI provides accurate atrophy assessment without
partial volume effects.
• CSF MRI data can be processed quickly without user
interaction.
• The measured T2 of the CSF is related to brain atrophy.
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EPI Echo planar imaging
eTE Effective echo time
GCA Global cortical atrophy
ICV Intracranial volume
MCI Mild cognitive impairment
M0 Equilibrium magnetization
MLEV Malcolm Levitt’s CPD sequence
MRI Magnetic resonance imaging




SVD Small vessel disease
T1 Longitudinal relaxation rate
T2 Transverse relaxation rate
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T2, CSF The T2 of cerebrospinal fluid
T2-
FLAIR
T2 fluid attenuation inversion recovery sequence
Introduction
Brain atrophy assessment is important in clinical and research
neuroradiology settings. When evaluating brain atrophy, tis-
sue loss is assumed when the peripheral and central cerebral
spinal fluid (CSF) spaces are enlarged in relation to the intra-
cranial volume [1]. Brain atrophy is an important imaging sign
in cerebral small vessel disease (SVD) [2], which is the most
common cause of vascular dementia and causes one-fifth of
all strokes worldwide [2, 3]. Also, brain atrophy predicts con-
version to Alzheimer’s disease (AD) in patients with mild
cognitive impairment (MCI) [4].
Brain atrophy can be evaluated by means of quantitative
brain volume measurements, or it can be visually scored by
means of rating scales such as the global cortical atrophy
(GCA) scale [5] and the medial temporal lobe atrophy
(MTA) scale [6, 7]. Quantitative brain volume measurements
are mainly used in research, because of their relative reliability
and good sensitivity compared to visual scores. Typically,
brain volume is expressed as a percentage of the intracranial
volume. This requires both a T1-weighted and a T2-weighted
sequence [1] in which the T1-weighted sequence is used to
assess brain volume, while the T2-weighted sequence is used
for the measurement of intracranial volume [1]. Currently, no
image segmentation method is completely accurate, as brain
tissue voxels containing CSF partial volume will bring in er-
rors in volume measurements, even with high-resolution im-
ages [8, 9]. Despite these inaccuracies, volumetric magnetic
resonance imaging (MRI) can predict conversion to AD in
accordance with the GCA and the MTA [10, 11]. So far, no
diagnostic threshold for computerized brain atrophy evalua-
tion has been established. Moreover, the currently available
segmentation techniques are not easily implemented in daily
clinical care. Therefore, visual rating scales remain the gold
standard in the clinical setting. Unfortunately, the GCA [5]
and the MTA scales [6, 7] suffer from subjectivity. Inter-
observer agreement for the GCA scale varies from poor to
substantial (kappas of 0.34 and 0.7) [5, 8], whereas the MTA
scale seems more robust with inter-observer agreements be-
tween 0.82 and 0.9 [12].
Recently, Qin [9] suggested a simple approach to map and
measure baseline CSF volume fraction [9] as a surrogate for
brain parenchymal volume, which could thus be used to eval-
uate brain atrophy. The approach is based on the long trans-
verse relaxation rate of CSF (T2,CSF) [13] as compared to other
tissue types [14]. It allows for measuring the CSF volume and
T2,CSF simultaneously. Apart from its potential as a surrogate
for brain atrophy measurements, the latter measurement (T2,
CSF) may reflect the CSF contents.
The main purpose of this study was to investigate the abil-
ity of this new, fast sequence (scan time of 1:11 min) to act as a
surrogate for brain atrophy. A second purpose was to measure




This study contains data from two ongoing studies in our
institution, which were both approved by the medical ethical
review board of the University Medical Center Utrecht
(Utrecht, The Netherlands). The experiments were performed
according to the guidelines and regulations of theWMO (‘Wet
Medisch wetenschappelijk Onderzoek’). Twenty-two subjects
were included as control subjects in a study of large vessel
disease (NL39070.041.11) and six subjects were included in
the ‘Parelsnoer’ study, which investigates cognitive disorders.
The inclusion criteria for the control subjects in the large ves-
sel disease study were: (1) no history of cerebrovascular dis-
ease or other brain diseases, and (2) no structural lesions seen
on MR imaging (conventional MRI and MR angiography).
Inclusion criteria for the subjects included in the ‘Parelsnoer’
study were: (1) patients referred to a memory clinic for the
evaluation of cognitive problems, and with a clinical dementia
rating scale of 0, 0.5 and 1 [15], and a Mini Mental State
Examination (MMSE) of 20 or higher [16]. Exclusion criteria
for the subjects included in the ‘Parelsnoer’ study were: (1)
Normal Pressure Hydrocephalus, (2) Morbus Huntington, (3)
history of cerebrovascular disease, (4) history of schizophre-
nia, bipolar disorder, psychotic symptoms or major depressive
disorder, (5) alcohol abuse, and (6) history of other brain dis-
eases (brain tumour, epilepsy, encephalitis). All subjects
signed informed consent. Data of subjects of both studies were
combined to obtain one pool of subjects with larger age and
brain atrophy variation. The mean (standard deviation, sd) age
of the subjects was 65 (12) years, range: 30–80 years. Of the
28 subjects, 19 subjects were male [mean (sd) age: 67 (11)
years, range: 30–80 years] and nine were female [mean (sd)
age: 63 (14) years, range: 30–79 years].
MR imaging
MR imaging was performed at 3 Tesla (Achieva, Philips,
Best, The Netherlands). A 3D T1-weighted sequence (ma-
trix 228x227, FOV 250×250×179 mm3, TR 7.2 ms, TE
3.5 ms, scan time 2:52 min) and CSF MRI (voxel 3×3×
6 mm3, TR 7917 ms, scan time 1:11 min) [9] were per-
formed. In the subjects who were part of the large vessel
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disease study, a higher resolution CSF MRI sequence (1×
1×4 mm3) was performed as well. The CSF MRI se-
quence exploits the long T2 properties of the CSF to ob-
tain a pure CSF map. By using a T2-preparation scheme,
the T2 decay within each voxel can be fitted, from which
the T2 can be estimated. Next, the fitted signal at TE=0
[BS(0)^] is compared to the signal of pure ventricular CSF
voxels, and based on this, the amount of CSF within each
voxel is estimated. This yields accurate measurements of
the CSF volume fraction (CSFVF) within the voxel [9].
From the obtained data, CSF volume maps and R2,CSF
(= the inverse of the T2,CSF) maps are obtained (Fig. 1).
More detailed information regarding the CSF sequence
can be found in the online supplementary material. In
Fig. 2, the sequence chart of the CSF MRI sequence is
shown. The R2,CSF maps were used to calculate the T2 of
the CSF. The CSF volume maps were used to estimate the
CSF volume (VCSF), which was expressed as a percentage
of intracranial volume. Based on the first echo (eTE=
0 ms) of the CSF MRI sequence, which includes both
parenchymal and CSF signal, the intracranial volume
(ICV) was measured. Region-of-interest (ROI) analyses
(Fig. 1c) were performed to obtain peripheral subarach-
noidal and ventricular CSF volumes and mean T2,CSF
values within these regions.
Data analysis
From the low and high resolution CSF MRI data, the follow-
ing CSF volumes were obtained: VCSF (total)=total CSF vol-
ume expressed as a percentage of ICV, VCSF (PS)=peripheral
subarachnoidal CSF volume expressed as a percentage of
ICV, VCSF (V)=ventricular CSF volume expressed as a per-
centage of ICV. The following T2,CSF values were obtained:
T2,CSF (total)=the mean T2,CSF value in the total CSF, T2,CSF
(PS)=mean T2,CSF value measured in the peripheral subarach-
noidal CSF, T2,CSF (V)=mean T2,CSF value measured in the
ventricles. Qualitative imaging scales [5–7] (Table 1) were
used to score (blinded) brain atrophy by two readers (J.H.,
experienced neuroradiologist, 10 years of experience and
J.B.D.V., 4 years of experience). The first reader (J.H.) scored
the images twice with an interval of one year in between. A
detailed description of this is given in the online supplemen-
tary material. To perform a standard quantitative
(computerized) brain atrophy evaluation, data of the 3D T1-
weighted sequence were processed using FMRIB Software
Library (FSL, FMRIB,Oxford, UK). For this, brain tissue
voxels of the T1-weighted sequence were isolated with the
brain extraction tool (BET) [17]. Subsequently, FAST
(FMRIB’s Automated Segmentation Tool) was used to obtain
grey matter, white matter and CSF maps, and from this, brain
parenchymal volumes were calculated.
Statistical analysis
Statistical analysis was carried out with R version 3.1.1 (R
Foundation for Statistical Computing, Vienna, Austria) [18]
and IBM SPSS statistics version 19.0.1 (SPSS Inc., Chicago,
Illinois). As an earlier study demonstrated that a quarter of
brain volume variation is explained by gender [19], we first
performed a Mann-Whitney U test to compare the distribution
of the GCA and MTA scores between male and female sub-
jects. Similarly, the ICV of males versus females were com-
pared, and the relative total CSF volumes of males versus
females were compared.
Cohen’s kappa statistics were used to evaluate the inter-
rater and intra-rater agreement for the GCA and MTA scores.
Linear regression analyses were used to correlate relative total,
peripheral subarachnoidal and ventricular CSF volumes (ob-
tained from the low resolution CSFMRI data) to the GCA and
MTA scores. Similarly, linear regression analyses were used
to correlate total, peripheral subarachnoidal, and ventricular
T2,CSF values to the GCA and MTA scores.
Linear regression analysis was performed to compare the
brain parenchymal volumes measured with the CSF MRI se-
quence to the brain parenchymal volumes measured with
FMRIB Software (based on a T1-weighted image).
Two analyses were performed to evaluate the influence of
partial volume effects on the obtained values. First, the results
of the low resolution CSF MRI sequence were compared
against the results of the high resolution CSF MRI sequence.
For this, the values obtained for global cortical atrophy and the
T2 measured within the peripheral subarachnoidal space were
compared using a paired samples t-test. Second, the ventricu-
lar ROI’s were eroded, after which the mean T2,CSF values
obtained from within these smaller ROIs were compared
against the mean T2,CSF values obtained within the actual ven-
tricular ROIs. To evaluate the difference between the results of
both these ROIs, a paired samples t-test was used.
In our study protocol no test-retest study was included, as
the earlier reproducibility test performed by Qin [9] demon-
strated an excellent robustness of the CSF MRI sequence for
measuring the CSF volumes and a good robustness for mea-
suring the T2,CSF (0.7<R
2<0.85). Though, as an attempt to
evaluate the agreement of the CSF MRI sequence within our
study, we compared the results of the low resolution CSFMRI
sequence against the results of the high resolution CSF MRI
sequence. This was done by means of a Bland-Altman scatter
plot analysis demonstrating the mean difference and limits of
agreement.
Results
Table 2 shows the mean, standard deviation (sd) and range of
GCA andMTA scores, ICVand relative total CSF volume. No
1256 Eur Radiol (2016) 26:1254–1262
significant differences in age, GCA and MTA scores, and
relative total CSF volume (18.1 % versus 16.0 %) between
males and females were found. ICVwas significantly different
in the males compared to the females (1524 cm3 versus
1361 cm3, p<0.01). The inter-rater agreements for the GCA
and MTA scores were moderate; 0.36 and 0.52 (p<0.01 and<
0.001). The intra-rater agreements for the GCA and MTA
scores were moderate to fair; 0.58 and 0.62 (p<0.001).
Brain atrophy and whole brain CSF measurements
Table 3 shows the number of subjects for each score on the
qualitative imaging scales (GCA and MTA scale) and their
corresponding mean (± sd) relative total CSF volumes (total
CSF volume expressed as a percentage of ICV), and mean (±
sd) total T2,CSF. The correlation between the GCA and the
MTA score and the relative total CSF volumes was significant
(R=+0.83 and +0.72, p<0.001). The correlation between the
GCA and the MTA score and total T2,CSF was significant
(R=+0.72 and +0.60, p<0.001 and<0.01).
Brain atrophy and regional CSF measurements
Figures 1 and 2 in the online supplementary material show the
correlation between the GCA and the MTA scores with rela-
tive peripheral subarachnoidal and ventricular CSF volumes
and T2,CSF. Table 4 shows the number of subjects for each
score on the qualitative imaging scales (GCA and MTA scale)
and their corresponding mean (± sd) relative peripheral sub-
arachnoidal and relative ventricular CSF volumes. The corre-
lations between the GCA scores and the relative peripheral
subarachnoidal and the relative ventricular CSF volumes were
significant (R=+0.78 and +0.78, p<0.001). The correlations
between the MTA scores and the relative peripheral subarach-
noidal and relative ventricular CSF volumes were significant
(R2=+0.62 and +0.86, p<0.001). The correlation between the
GCA scores and the peripheral subarachnoidal and ventricular
T2,CSF values were significant (R=+0.70 and +0.49, p<0.001
and<0.01). The correlation between the MTA scores and the
peripheral subarachnoidal and ventricular T2,CSF values were
significant (R=+0.57 and +0.41, p<0.01 and<0.05) (Table 5).
Fig. 1 A) CSF M0 map; the signal in each voxel is scaled to pure
ventricular voxels to estimate the partial volume effect from which the
CSF volume can be calculated. B) R2 (= the inverse of the T2) CSF map.
C) Regions of interest used to retrieve the peripheral subarachnoidal (red)
and ventricular T2, CSF values
Fig. 2 CSF MRI sequence chart, the sequence is built of three parts. (1)
Part 1, a nonselective (NS) saturation pulse followed by a time delay. (2)
Part two, a NSMLEV T2-preparation, based on a τCPMG of 70 ms and 0,
4, 8, and 16 refocusing pulses. From these, effective TEs of 0, 280, 560,
and 1120 ms are created. (3) In between parts 2 and 3, an optional inver-
sion pulse can be applied which can compensate for slice-timing differ-
ences in multi-slice readout. (4) Part three, a multi-slice single-shot echo
planar imaging (EPI) readout
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CSF MRI sequence versus standard computerized brain
atrophy evaluation
In one subject, the computerized segmentation failed during
brain extraction and this subject was thus excluded from the
analysis. Themean (sd) brain volumemeasured using the CSF
MRI sequence was 1212 (122) ml. The mean (sd) brain vol-
ume derived from the 3D-T1w MRI sequence was 1008 (106)
ml. The brain parenchymal volumes (BPV), measured by
means of the CSF MRI sequence and the 3D-T1w MRI se-
quence showed a very strong correlation: R=0.85, BPVCSF-
MRI=232 (± 123)+0.97 (± 0.12)·BPV3D-T1wMRI, p<0.01.
Table 1 GCA and MTA scale
GCA scale for global cortical atrophy
Score
0 No cortical atrophy
1 Mild atrophy: opening of sulci
2 Moderate atrophy: volume loss of gyri
3 Severe atrophy: ‘knife blade’ atrophy’
MTA scale for medial temporal lobe atrophy
Score
0 No atrophy
1 Only widening of choroid fissure
2 Also widening of temporal horn of lateral ventricle
3 Moderate loss of hippocampal volume (height)
4 Severe volume loss of hippocampus
Table 2 Subject characteristics
All Male Female
N 28 19 9
Age
Mean (sd) 65 (12) 67 (11) 63 (14)
Range 30 – 80 30 – 80 30 – 79
GCA
Mean (sd) 1 (1) 1 (1) 1 (1)
Range 0 – 2 0 – 2 0 – 2
MTA
Mean (sd) 1 (1) 1 (1) 1 (1)
Range 0 – 4 0 – 4 0 – 2
ICV (cm3)
Mean (sd) 1471 (146) 1524 (115) 1361 (148)
Range 1081 – 1655 1306 – 1655 1081 – 1552
VCSF (total) (%)
Mean (sd) 17.4 (4.3) 18.1 (4.0) 16.0 (4.7)
Range 11.1 – 26.1 12.1 – 25.5 11.1 – 26.1
GCA, global cortical atrophy; MTA, medial temporal lobe atrophy; ICV,
intracranial volume; VCSF (total), relative total cerebrospinal fluid (CSF)
volume (= total CSF volume expressed as a percentage of intracranial
volume); sd, standard deviation
Intracranial volume was significantly different between males and fe-
males (p<0.01). No significant differences in age, GCA and MTA score
were found






0 5 12.5±1.1 1182±60
1 17 16.7±2.6 1339±111
2 6 23.5±2.5 1528±138
3 – – –
Correlation R=+0.83 (p<0.001) R=+0.72 (p<0.001)
MTA
0 11 15.0±3.2 1255±109
1 11 16.7±2.7 1360±130
2 3 21.6±4.3 1512±211
3 2 25.0±0.7 1506±71
4 1 23.7 1522
Correlation R=+0.72 (p<0.001) R=+0.60 (p<0.01)
GCA, global cortical atrophy; MTA, medial temporal lobe atrophy; VCSF
(total), relative total cerebrospinal fluid (CSF) (= total CSF volume
expressed as a percentage of intracranial volume); T2,CSF (total), the mean
T2 value of the total cerebrospinal fluid
For each category of GCA and MTA score, the CSF volume and the
T2,CSF are shown






0 5 10.1±0.9 1.0±0.3
1 17 13.2±2.0 1.7±0.7
2 6 17.5±2.3 3.7±0.9
3 – – –
Correlation R=+0.78 (p<0.001) R=+0.78 (p<0.001)
MTA
0 11 12.1±2.6 1.2±0.4
1 11 13.0±2.0 1.9±0.7
2 3 16.2±3.7 3.3±0.2
3 2 19.1±0.1 3.3±0.7
4 1 16.5 5.4
Correlation R=+0.62 (p<0.001) R=+0.86 (p<0.001)
GCA, global cortical atrophy; MTA, medial temporal lobe atrophy; VCSF
(PS), relative peripheral subarachnoidal cerebrospinal fluid (CSF) volume
(= peripheral subarachnoidal CSF volume expressed as a percentage of
intracranial volume); VCSF (V), relative ventricular CSF volume ( = ven-
tricular CSF volume expressed as a percentage of intracranial volume).
For each category of GCA and MTA score, the VCSF (PS) and the VCSF
(V) are shown
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Partial volume effects
The peripheral subarachnoidal CSF volumes, measured by
means of a low (12.5±2.3 %) and a high resolution (11.8±
4.7 %) CSF MRI sequence, were not significantly different
(p=0.38). The T2 of the CSF within the peripheral subarach-
noidal space as measured by means of a low (1275±129 ms)
and high resolution (1420±183 ms) CSF MRI sequence were
significantly different (p<0.001). The mean (sd) T2,CSF in the
ventricular mask was 1912 (145) ms. The mean (sd) T2,CSF in
the eroded (smaller) ventricular ROI was 2060 (153) ms. The-
se were significantly different (p<0.001).
Agreement analysis
In Fig. 3, a Bland-Altman scatter plot demonstrates the agree-
ment between the low and high resolution CSFMRI sequence
for both the total CSF volume and the T2,CSF. The mean dif-
ference of the total CSF volume was 30.8 (± 70.7) ml. This
difference was not significant (p=0.054). Themean difference
of the T2,CSF was -161.4 (± 132) ms (p<0.001).
Discussion
We demonstrated that a fast CSF MRI sequence with an im-
aging time of 1:11 minutes and fast post-processing without
user interaction can be used to obtain the intracranial volume,
the CSF volume and the T2 relaxation time constant of the
CSF. The obtained volumemeasurements correlated well with
the qualitative atrophy scales, which show that the CSF MRI
sequence can be used to evaluate brain atrophy. We found a
high correlation between the T2 of the CSF and the qualitative
atrophy scales. The T2 of the CSF could thus be a marker for
neurodegenerative diseases.
Over the last few years, an increasing number of research
groups have started to use image segmentation tools, which are
used to measure the brain parenchymal volume, instead of qual-
itative image atrophy scores to evaluate brain atrophy. In this
paper, the percentage of CSF was used as a surrogate for brain
parenchymal volume. The method that we used to obtain the
CSF volume exploits the long T2 of the CSF to isolate its signal.
By fitting T2 decay within each voxel, and comparing the fitted
signal at TE=0 [BS(0)^] to the signal of pure ventricular CSF
voxels, the amount of CSF within each voxel is estimated. This
yields accurate measurements of the CSF volume fraction within
the voxel [9], from which regional CSF volumes can be obtain-
ed. We limited ROI analyses to the peripheral subarachnoidal
and the ventricular space. However, this could be extended to
obtain measurements of, for instance, frontal, parietal or tempo-
ral CSF volume, and thus provide an assessment of regional
atrophy. Regional atrophy assessment could potentially enable
classification of dementia diseases based on their atrophy pat-
terns [20]. For instance, AD and frontotemporal lobe degenera-
tion are both associated with medial temporal lobe atrophy
[21–24]. The combined presence of either temporal and posteri-
or, or temporal and frontal atrophy may help to distinguish be-
tween both [25–27]. Additionally, regional measurements could
be helpful when differentiating ventriculomegaly or hydroceph-
alus from brain atrophy. Enlarged ventricular CSF volume with-
out an increase in peripheral subarachnoidal CSF volume could
guide the assessor towards ventriculomegaly or hydrocephalus
instead of brain atrophy. It should be noted that the CSF MRI
sequence cannot differentiate between gray or white matter loss,
and as such, can only supplement conventional MRI sequences
but not replace them.
In this paper, we compared the results of the brain parenchy-
mal volume measurements obtained from our CSF MRI se-
quence to the results of a more standard computerized quantita-
tive brain atrophy evaluation. We demonstrated a strong corre-
lation between both brain parenchymal volume measurements.
The linear analysis showed that our CSF MRI sequence esti-
mates the ICV as systematically larger than the T1-based seg-
mentation method by about 230 ml. This is probably due to a
slight difference, in between both methods, in the exact
(subvoxel) localization of the border between CSF and tissue.
As well, small amounts of variation may be explained by partial
volume effects in either the 3D-T1w sequence, caused by the
inclusion of brain tissue in CSF voxels, or by partial volume
effects in our CSF MRI sequence, which are discussed below.
More recent segmentation softwaremay perform even better, but






0 5 1150±70 1774±217
1 17 1305±117 1992±111
2 6 1493±142 2000±86
3 – – –
Correlation R=+0.70 (p<0.01) R=+0.49 (p<0.01)
MTA
0 11 1225±112 1834±176
1 11 1324±139 1954±98
2 3 1479±218 1965±96
3 2 1478±71 1930±10
4 1 1466 2125
Correlation R=+0.57 (p<0.01) R=+0.41 (p<0.05)
GCA, global cortical atrophy; MTA, medial temporal lobe atrophy;
T2,CSF (PS), the mean T2 value of the peripheral subarachnoidal cerebro-
spinal fluid; T2,CSF (V), the mean T2 value of the ventricular cerebrospinal
fluid
For each category of GCA andMTA score, the T2,CSF (PS) and the T2,CSF
(V) are shown
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the scope of our comparison was to compare to standard avail-
able segmentation software.
An earlier study demonstrated that over half of the variation in
brain volume can be explained by ICV and a quarter of the
variation in brain volume can be explained by gender [19]. This
was confirmed in our study, as we demonstrated a significantly
different ICV in male compared to female subjects. The strength
of the approach presented in this paper is that it accounts for this
variation by expressing CSF volumes as a ratio to the ICV.
We found an increase in the T2,CSF with increased visual
ratings of global cortical and medial temporal lobe atrophy.
Qin suggested that the regional variation in T2,CSF is likely ex-
plained by variation in the composition of the CSF [9]. The CSF
composition in patients can be different due to both differences
in O2 partial pressure and differences in CSF protein content.
Zaharchuk found a profound effect of oxygen partial pressure
on the longitudinal relaxation rate (T1) of the CSF [28]. Even
more so, they showed that inhalation of 100 % oxygen changed
the T1 of CSF, an effect which was most pronounced in the
cortical sulci [29]. This matches with our findings, which show
that the T2 of the peripheral subarachnoidal CSF has a stronger
relationship with the GCA and MTA scale than the T2 of the
ventricular CSF. We hypothesize that subjects with more brain
atrophy have a lower oxygen content of CSF. Small vessel dis-
ease could lead to decreased brain perfusion and thus decreased
oxygen diffusion from the blood vessels towards the CSF. A
decrease in oxygen content would lead to a longer T2, which
would correspond to our observations. Unfortunately, we were
not able to measure the partial oxygen pressure of CSF in our
subjects and thus to investigate this phenomenon. Further re-
search with dedicated measurements of the partial oxygen pres-
sure in the CSF are needed to investigate this. So far, the partial
oxygen pressure of the CSF within this patient population has
not been investigated, as the measurements are rather difficult to
perform.Besides oxygen pressure, changes in the protein content
of the CSF related to pathology should be investigated as a
potential explanation for the regional variation in T2 of the
CSF. Moreover, though Qin [9] suggested variation in composi-
tion of the CSF as themost likely source for variation in T2 of the
CSF, it may still be possible that the T2 mapping sequence yields
systematic errors in the estimated T2. These might be related to
partial volume effects and imperfections in the excitation and
refocusing pulses (heterogeneity in the transmit RF field, B1).
Thus, the reproducibility of themethod and its robustness against
B1 variation (due to the use of an MLEV T2 preparation
scheme) should be established in future studies before firm con-
clusions on the origin of regional T2 variation can be drawn.
In this paper, an MLEV scheme was selected based on the
initial work of Qin [9]. The advantage of the pre-pulse ap-
proach is that it can match resolution and coverage to other
functional scans suchASL and functionalMRI. This increases
the abilities to perform partial volume corrections within these
modalities, which is especially important in populations with
varying degrees of atrophy.
Although the CSF MRI sequence seems promising, there
are some limitations. One of them is partial volume effects,
which could have potentially influenced our results and the
found correlations. However, several observations demonstrate
that the partial volume effects had no major influence on the
results. First, the ventricles should be more or less free of
partial volume effects, and we demonstrated that the correla-
tions with the GCA andMTA scores hold true even when only
the ventricular CSF volume or T2,CSF were evaluated. In addi-
tion, eroding the ventricular masks to smaller ROIs only had a
minor influence on the T2,CSF values. Second, we investigated
the influence of partial volume effects by comparing the results
obtained with a low resolution (3×3×6 mm3) CSF MRI se-
quence to the results obtained with a high resolution CSFMRI
sequence (1×1×4mm3) and found no significant difference
between the peripheral subarachnoidal CSF volumes.
Fig. 3 Bland-Altman plot demonstrating the agreement between the low
and high resolution CSF MRI sequence performed within the same
session. The coefficient of repeatability for the relative CSF volumes
(figure on the left, CSF volumes expressed as a percentage of
intracranial volume), was 14. The coefficient of repeatability for the T2
within the total CSF was 9.5
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However, the difference in between the T2,CSF, measured with
both the low and high resolution CSF MRI sequence in the
peripheral subarachnoidal space, was significant. As explained
before, this may indicate that the T2 has a higher sensitivity to
partial volume effects than the CSF volume measurements.
In conclusion,we demonstrated that a fast CSFMRI sequence
has the potential to replace qualitative imaging atrophy scales and
supplement conventional segmentation methods. The method is
advantageous, as it requires little post-processing time and no
user interaction. The T2,CSF should be investigated more thor-
oughly, as it could be a marker for neurodegenerative diseases.
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